How Do You Choose?
Caris Target Now™ provides the clinically relevant information physicians need to develop individualized cancer treatment strategies.
Choosing the appropriate treatment(s) for patients with cancer has always been complex. Within standard of care, physicians often must make difficult choices between multiple therapies — none of which are guaranteed to work for any individual patient. And when it comes to patients for whom standard treatments aren’t an option — either because the cancer is rare and/or aggressive, or there are co-morbidities or, worst of all, because standard treatments were unsuccessful — oncologists face even more difficult treatment decisions.
Many cancer drugs, including traditional chemotherapies, hormone therapies and newer targeted and biologic treatments have been shown to be associated with specific genes or proteins known as cancer biomarkers. With molecular profiling we can identify the biomarkers specific to an individual patient’s tumor, which can help inform the therapy selection process.
By combining molecular profiling with an extensive review of the world’s most relevant research on biomarkers and their correlation with drug response, Caris Target Now identifies therapeutic agents with potential benefit, and potential lack of benefit, and may reveal treatments not previously considered. This information enables physicians to develop clinically actionable, individualized cancer treatment strategies.
Caris Target Now tests all clinically relevant biomarkers, including FDA-approved companion diagnostics. Biomarkers tested may include these and others:
|AR||Flutamide; Goserelin; Leuprolide; Gonadorelin; Bicalutamide|
|BRAF||Panitumumab; Vemurafenib; Cetuximab|
|EGFR||Cetuximab; Gefitinib; Panitumumab; Erlotinib|
|ER||Toremeifene; Fulvestrant; Megestrol acetate; Erlotinib; Tamoxifen; Medroxyprogesterone; Exemestane; Anastrozole; Gefitinib; Panitumumab; Letrozole|
|ERCC1||Cisplatin; Carboplatin; Oxaliplatin|
|HER2||Liposomal doxorubicin; Trastuzumab; Doxorubicin; Lapatinib; Epirubicin|
|KIT||Sunitinib; Imatinib; Sorafenib|
|KRAS||Erlotinib; Panitumumab; Cetuximab; Gefitinib; Sorafenib|
|MRP1||Methotrexate; Vinblastine; Doxorubicin; Epirubicin; Vinorelbine; Vincristine|
|PGP||Liposomal doxorubicin; Vincristine; Docetaxel; Vinorelbine; Etoposide; Epirubicin; Epirubicin; Paclitaxel; Vinblastine; Doxorubicin|
|PIK3CA||Lapatinib; Panitumumab; Cetuximab; Trastuzumab|
|PR||Gonadorelin; Toremifene; Fulvestrant; Megestrol acetate; Medroxyprogesterone; Letrozole; Exemestane; Goserelin; Tamoxifen; Leuprolide; Anastrozole|
|PTEN||Panitumumab; Gefitinib; Trastuzumumab; Erlotinib; Cetuximab|
|TOP2A||Liposomal doxorubicin; Epirubicin; Doxorubicin|
|TS (TYMS)||Capecitabine; Pemetrexed; Fluorouracil|
|TUBB3||Vinorelbine; Docetaxel; Paclitaxel|
* Biomarker status (overexpressed, underexpressed, positive or negative for specific mutations, etc.) determines whether that biomarker is associated with response, lack of response or resistance to each treatment. Treatment associations are from published, peer-reviewed medical literature. Citations available upon request.
Learn more about treatments associated with specific biomarkers at CarisTargetNow.com, a new resource for physicians to learn more about applying cutting-edge cancer research to real-world cancer treatment today.
Learn more about ordering and using Caris Target Now for your patients.
Or request a call from a Caris Target Now rep.
Find a local doctor who can help you determine if Caris Molecular Intelligence Service may be right for you.